DDInter1268 DDInter624
Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for multiple sclerosis. Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA. Natalizumab was approved by the European Commission on September 22, 2023.
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Natalizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Natalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Naltrexone {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Natalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bedaquiline
Bedaquiline {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Efavirenz
Natalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Naltrexone {u} (Compound) causes {v} (Side Effect) Hepatitis
Hepatitis {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Fludarabine
Fludarabine {u} (Compound) causes {v} (Side Effect) Discomfort
Discomfort {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Fingolimod {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Efavirenz
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Efavirenz
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) downregulates {v} (Gene) RFC2
RFC2 {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Lomitapide {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Efavirenz
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Methotrexate
Methotrexate {u} (Compound) upregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Natalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Efavirenz (Compound)
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Efavirenz (Compound)
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline and Bedaquiline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Efavirenz (Compound)
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Efavirenz (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Fludarabine and Fludarabine (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Efavirenz (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Efavirenz (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Efavirenz (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) downregulates RFC2 (Gene) and RFC2 (Gene) is downregulated by Efavirenz (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Efavirenz (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate (Compound) upregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Efavirenz (Compound)